The manufacturing technology was transferred from a cancer research institution where Reqorsa was discovered and had previously been manufactured. It has now been manufactured at commercial scale in a current good manufacturing practices-compliant facility for the first time, according to Genprex.

Reqorsa is comprised of a tumor suppressor candidate 2 (TUSC2) plasmid DNA that's encapsulated in nonviral nanoparticles that are administered intravenously and designed to target tumor cells.

The firm said it believes production and process improvements will result in a scalable, reproducible, and stable drug product suitable for storage, shipment, and patient use. In addition, Genprex also believes it's on track to complete manufacturing of clinical-grade Reqorsa to supply the company's upcoming Acclaim-1 and Acclaim-2 clinical trials. These trials, which will combine Reqorsa with, respectively, AstraZeneca's Tagrisso and Merck's Keytruda drugs, are expected to begin in the first half of 2021.